Current status and future perspectives in immunotherapy for glioblastoma
Olivia Rongze Lu, PhD, University of Texas at Austin and Dell Medical School, Austin, TX, gives us an update on the current immunotherapeutic landscape for glioblastoma and outlines promising ongoing clinical trials, highlighting challenges in the development of effective immunotherapies for glioblastoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Видео Current status and future perspectives in immunotherapy for glioblastoma канала VJOncology
Видео Current status and future perspectives in immunotherapy for glioblastoma канала VJOncology
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC](https://i.ytimg.com/vi/oJvZuVjOBJk/default.jpg)
![EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC](https://i.ytimg.com/vi/d3rLVqNG-14/default.jpg)
![Safety and preliminary evidence for efficacy for propranolol + pembrolizumab in metastatic melanoma](https://i.ytimg.com/vi/TPyaEvucxao/default.jpg)
![OPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancer](https://i.ytimg.com/vi/n6gpNKp66KA/default.jpg)
![AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab](https://i.ytimg.com/vi/hN101PjDcZk/default.jpg)
![Real-world toxicities associated with lorlatinib in ALK+ NSCLC](https://i.ytimg.com/vi/OokKfNU8Ml4/default.jpg)
![What to do in patients with early-stage TNBC who have not achieved a pCR?](https://i.ytimg.com/vi/rEQ9vYDczrE/default.jpg)
![Bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity](https://i.ytimg.com/vi/U2uSNTZRUQ8/default.jpg)
![Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC](https://i.ytimg.com/vi/m1ectCO3QNM/default.jpg)
![Current treatment recommendations and future directions for EGFR-mutant NSCLC](https://i.ytimg.com/vi/mp3apAnwjFc/default.jpg)
![Does every patient with localized muscle-invasive bladder cancer need a cystectomy?](https://i.ytimg.com/vi/ut81rE4V5uY/default.jpg)
![The future of immunotherapy in melanoma](https://i.ytimg.com/vi/x9chJq3Xd8k/default.jpg)
![Identifying who requires a CT scan in staging for brain tumors](https://i.ytimg.com/vi/PxNQ70fSPyI/default.jpg)
![Bias and microaggressions in healthcare](https://i.ytimg.com/vi/kPOEX66P-E0/default.jpg)
![Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091](https://i.ytimg.com/vi/YLoFH1sgamA/default.jpg)
![Challenges of desmoid tumors](https://i.ytimg.com/vi/kEZAyyqWA4E/default.jpg)
![Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancer](https://i.ytimg.com/vi/XJYAdrXjDbA/default.jpg)
![VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer](https://i.ytimg.com/vi/E2VvZMZTwZg/default.jpg)
![Kidney cancer: post-surgery sorafenib](https://i.ytimg.com/vi/wc3gIwh93V0/default.jpg)
![Highlighting problems in personalized medicine](https://i.ytimg.com/vi/19v93717hxQ/default.jpg)
![Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC](https://i.ytimg.com/vi/UMhutwBLsHY/default.jpg)